site stats

Syros pharmaceuticals merger

WebSep 15, 2024 · Following the closing of the Merger, the combined company will trade on The Nasdaq Global Select Market under the ticker symbol "SYRS," and will be led by Syros’ existing management team,... WebMar 2, 2024 · Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Dec 12, 2024 Syros Pharmaceuticals Announces Publication in Blood Advances …

TYME stock surges on merger agreement with Syros Pharmaceuticals …

WebSep 15, 2024 · Following the closing of the Merger, the combined company will trade on The Nasdaq Global Select Market under the ticker symbol “SYRS,” and will be led by Syros’ … WebApr 7, 2024 · Syros Pharmaceuticals is part of the Pharmaceuticals industry, and located in Massachusetts, United States. Syros Pharmaceuticals Location 35 Cambridge Park Dr, Cambridge, Massachusetts, 02140, United States Description Read More Industry Pharmaceuticals Healthcare Discover more about Syros Pharmaceuticals Beth Ann Work … bebes miniaturas https://mildplan.com

Syros Pharmaceuticals, Inc.

WebNov 14, 2024 · Closed Merger with TYME Technologies and Concurrent PIPE; Proceeds from Combined Transactions Augment Cash Balance, Ending Third Quarter with … WebJul 5, 2024 · Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement News Download as PDF July 05, 2024 Combined Company Will Operate as Syros Pharmaceuticals and Continue to Advance … WebApr 15, 2024 · Syros Pharmaceuticals, Inc engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by... divisor\u0027s jx

TYME stock surges on merger agreement with Syros Pharmaceuticals …

Category:Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Receives Average ...

Tags:Syros pharmaceuticals merger

Syros pharmaceuticals merger

Syros and Tyme Technologies Announce Stockholder Approval of Merger …

WebSyros Pharmaceuticals, Inc. 35 CambridgePark Drive, 4th Floor . Cambridge, Massachusetts 02140 (617) 744-1340 (Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service) Copies to: Nancy Simonian, M.D. President and Chief Executive Officer. WebJul 5, 2024 · Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement Business Wire July 5, 2024, 4:00 AM · 16 …

Syros pharmaceuticals merger

Did you know?

WebJul 5, 2024 · Syros Pharmaceuticals Inc (NASDAQ: SYRS) has agreed to acquire TYME Technologies Inc (NASDAQ: TYME ), including its pipeline assets and net cash, after … WebApr 15, 2024 · Syros Pharmaceuticals has a 1-year low of $2.42 and a 1-year high of $12.93. Syros Pharmaceuticals (NASDAQ:SYRS – Get Rating) last released its quarterly earnings …

WebSep 16, 2024 · CAMBRIDGE, Mass., September 16, 2024 -- ( BUSINESS WIRE )--Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that … WebJul 5, 2024 · Development stage biotech firms Syros Pharmaceuticals ( SYRS) and Tyme Technologies ( NASDAQ: TYME) announced on Tuesday that the companies entered into …

WebJul 5, 2024 · Concurrent with the merger, Syros announced an oversubscribed $130 million private investment in public equity (PIPE) financing at a price per unit of $0.94. New and …

WebKEY WINS: Steered the strategic and operational integration of Tyme Inc. into Syros Pharmaceuticals following an acquisition. Now driving business for an artificial intelligence-powered...

WebSep 15, 2024 · The new CUSIP number for Syros’ common stock following the reverse stock split is 87184Q206. On September 15, 2024, the holders of a majority of Syros’ … bebes nenucos youtubeWebSep 20, 2024 · Syros Pharmaceuticals has recently acquired its peer Tyme Technologies. The sole purpose of the merger was to acquire TYME's cash balance. Concurrently with … divisor\u0027s jwWebJul 5, 2024 · In the merger, Syros expects to issue approximately 74.3 million shares of its common stock to TYME stockholders to acquire TYME's expected net cash at closing and … bebes musicaWebExhibit 4.2 . SYROS PHARMACEUTICALS, INC. and . Trustee . INDENTURE . Dated as of SENIOR DEBT SECURITIES divisor\u0027s jrWebTyme Technologies, Inc., a biotechnology company developing cancer metabolism-based therapies, completed its acquisition by merger with Syros Pharmaceuticals, Inc., a leader … divisor\u0027s k3WebSep 16, 2024 · CAMBRIDGE, Mass.-- ( BUSINESS WIRE )--Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of … bebes mulatosWebJul 5, 2024 · In the merger, Syros expects to issue approximately 74.3 million shares of its common stock to TYME stockholders to acquire TYME’s expected net cash at closing and … bebes meninas lindas